December 1, 2017
Innovative Technology Eliminates Risk of Backflow and Reduces Risk of Cross Contamination
Cantel Medical Corp. subsidiary, Crosstex International, Inc. (“Crosstex”), continues its market diversification and expansion with the acquisition of SAFE-FLO® Saliva Ejector products from RJC Products LLC (“RJC Products”). This patented technology eliminates backflow, thus reducing the risk of cross-contamination from patient to patient and improving the infection prevention protocol within the dental practice.
“We are excited to add the SAFE-FLO Saliva Ejector family of products to our existing product portfolio of Saliva Ejectors and HVE Tips. As a recognized leader, this addition enhances our portfolio and is in line with our mission to provide innovative infection prevention solutions that improve and enhance the patient experience,” stated Gary Steinberg, President & CEO, Crosstex. “Backflow has long been a major concern of the dental profession and the addition of the SAFE-FLO Saliva Ejector product portfolio will further enable us to help eliminate this risk while providing added safety and comfort for the patient.”
“Crosstex is the ideal partner as its suite of high quality, innovative products combined with SAFE-FLO Saliva Ejector industry leading technology will help eliminate backflow and reduce the risk of cross contamination during dental procedures,” stated Rich Bushman, President, RJC Products. “The addition of SAFE-FLO Saliva Ejector products will not only enhance Crosstex’s portfolio, but also help protect patients from the risk of infection.”
Crosstex, a Cantel Medical company, manufactures a wide array of unique and innovative infection prevention and compliance products for the global healthcare industry. Founded in 1953 and headquartered in Hauppauge, New York, Crosstex is a recognized leader for its portfolio of waterline treatment, biological monitoring, sterility assurance packaging and personal protection equipment (PPE). Sold in more than 100 countries, the range of products distributed to medical, dental and veterinary practices and facilities include our award winning (5 consecutive years) SECURE FIT® Face Masks, DENTAPURE® Waterline Treatment Cartridges and Liquid Ultra® Solution, SURE-CHECK® Sterilization Pouches with internal/external multi-parameter indicators, TYVEK® Pouches with 510K approval, STEAMPLUS™ Type 5 Chemical Integrators, CONFIRM® Monitoring System and PASSPORT® Plus In-Office and Mail-In Biological Indicators, RAPACIDE® OPA/28 High Level Disinfectant, AXESS™ Anesthetic Mask and ClearView™ Nasal Mask.
For information on the full line of Crosstex infection prevention, patient safety and compliance products, please contact Crosstex at 631-582-6777 or visit www.crosstex.com.
About Cantel Medical Corp.
Cantel Medical is a leading global company dedicated to delivering innovative infection prevention and control products and services for patients, caregivers, and other healthcare providers which improve outcomes, enhance safety and help save lives. Our products include specialized medical device reprocessing systems for endoscopy and renal dialysis, advanced water purification equipment, sterilants, disinfectants and cleaners, sterility assurance monitoring products for hospitals and dental clinics, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates, hollow fiber membrane filtration and separation products, and specialty packaging for infectious and biological specimens. Additionally, we provide technical service for our products.
For further information, visit the Cantel website at www.cantelmedical.com.
About RJC Products LLC
RJC Products is a company focused on commercializing innovative new products. We work to solve problems with innovative and elegant solutions that provide great value to those who use our products. Our growth is fueled from organic new product development as well as partnerships and working relationships with other firms.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel’s filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.